Approval · Notice of Compliance 31302 · 2023
HULIO: Notice of Compliance 31302
Issued July 20, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31302
- Date
- July 20, 2023
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
- Canadian reference product
- HUMIRA
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HULIO | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 20 MG per SYR
- ADALIMUMAB 40 MG per SYR
- ADALIMUMAB 40 MG per PEN